Citation Impact
Citing Papers
Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma
2007 Standout
Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer
2004
Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours
1999
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies
2000
The GH–IGF-I axis and breast cancer
2003
Growth Hormone Receptor Antagonists
2004
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Nanoparticles in cancer therapy and diagnosis
2002 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease
2008
Sex bias in neuroscience and biomedical research
2010 Standout
Anthrazykline in der Krebstherapie
1997 Standout
WHO-EORTC classification for cutaneous lymphomas
2005 Standout
Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.
1998
The Potent Somatostatin Analogue Vapreotide Does Not Decrease Pancreas-Specific Complications After Elective Pancreatectomy: A Prospective, Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial
2003
Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome
2015
Osteosarcoma treatment – Where do we stand? A state of the art review
2013 Standout
Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group
2005
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery
2010 Standout
Pharmacokinetics and toxicity of intraarterial Adriamycin for hepatocellular carcinoma: Effect of coadministration of lipiodol
1991
Polymer conjugates as anticancer nanomedicines
2006 Standout
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
2004 Standout
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
2001 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Current management strategies for cutaneous T-cell lymphoma
2004
Acromegaly: An Endocrine Society Clinical Practice Guideline
2014 Standout
Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma
2003
Advances in Pediatric MR Imaging
2008
Epirubicin
1993
Treatment of Cutaneous T Cell Lymphoma
2002
Quality-of-Life Improvements in Cutaneous T-Cell Lymphoma Patients Treated with Denileukin Diftitox (ONTAK®)
2002
Epirubicin
1997
Postoperative pancreatic fistula: An international study group (ISGPF) definition
2005 Standout
Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy
1992
Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol
2008
Sex- and Age-Related Chemotherapy Toxicity in Patients with Non-Metastatic Osteosarcoma
2009
Review of extracorporeal photopheresis in early‐stage (IA, IB, and IIA) cutaneous T‐cell lymphoma
2007
Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs
2002
The dawning era of polymer therapeutics
2003 Standout
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Phase I Study of Vinorelbine and Docetaxel with Granulocyte Colony-Stimulating Factor Support in the Treatment of Metastatic Breast Cancer
2002
Gender differences in drug responses
2006
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Clinical pharmacokinetics of doxorubicin in hepatoma patients after a single intravenous injection of free or nanoparticle-bound anthracycline
1989
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
2006 Standout
Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment
2009 Standout
Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway
2017 StandoutNobel
Oral Idarubicin in Solid Tumour Chemotherapy
1995
Policy: NIH to balance sex in cell and animal studies
2014 StandoutNature
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
2004 Standout
EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer.
1997 Standout
Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer
2002
The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth
2000
Erythrodermic mycosis fungoides and Sézary syndrome treated with extracorporeal photopheresis as part of a multimodality regimen: A single‐centre experience
2015
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
2007 Standout
Diffusion-Weighted MRI in the Body: Applications and Challenges in Oncology
2007 Standout
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
2012 Standout
Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group
2003
Anthraquinones As Pharmacological Tools and Drugs
2016 Standout
The role of extracorporeal photopheresis in the management of cutaneous T‐cell lymphoma, graft‐versus‐host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society
2017
Works of N Dobbs being referenced
Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer
1999 Nobel
Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry
1995
Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests
1992
A phase II, multicentre, UK study of vinorelbine in advanced breast cancer
1994
Doxorubicin pharmacokinetics: the effect of abnormal liver biochemistry tests
1998
Estimation of doxorubicin and doxorubicinol by high-performance liquid chromatography and advanced automated sample processor
1987
Phosphorus-31 metabolism of human breast—an in vivo magnetic resonance spectroscopic study at 1.5 Tesla
1994
Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven Hospital experience.
1990
Patient acceptability and practical implications of pharmacokinetic studies in patients with advanced cancer
1993